NextCure, Inc. announced that the FDA has granted Fast Track Designation for SIM0505, an investigational ADC, for treating platinum-resistant ovarian cancer. SIM0505 comprises an antibody targeting CDH6 and a TOPO1 inhibitor. This news was shared on April 7, 2026. NextCure, Inc. is dedicated to developing innovative cancer therapies. SIM0505's Fast Track Designation expedites the drug's review process, potentially accelerating its availability for patients in need. This development marks a significant step in advancing cancer treatment research.